Ad hoc Release Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz) Biofrontera AG: Licensing Agreement for Ameluz® in Israel with Perrigo Israel Agencies Ltd.

Leverkusen, 6 January 2014 - Biofrontera Pharma GmbH, a fully-owned subsidiary of Biofrontera AG, has today signed an agreement with Perrigo Israel Agencies Ltd. for the marketing of Ameluz® and BF- RhodoLED® in Israel. In December 2011, Ameluz® received the
centralized European approval as medicinal product for the first-line treatment of mild and moderate actinic keratosis. Ameluz® is used together with a red-light source, such as Biofrontera's BF-RhodoLED®, in photodynamic therapy (PDT), by which tumor cells in the skin are selectively killed. The treatment results in high cure rates with outstanding cosmetic result. The agreement includes profit sharing and milestone payments.
Perrigo Company plc is a global pharmaceutical company with fiscal year 2013 sales of approximately US$3.5 billion. Perrigo Israel is active in both medicinal products and medical devices. It holds a leading position in the field of dermatology in Israel.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen

ISIN: DE0006046113

WKN: 604611

Contact: Biofrontera AG

Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290

E-mail: h.luebbert@biofrontera.com

Page 1

distributed by